ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates

ARS Pharmaceuticals reported a quarterly EPS loss of $0.42, in line with the Zacks consensus, versus EPS of $0.52 a year ago — a year-over-year swing of $0.94 to the downside. The print meets expectations but the move from profit to loss signals a meaningful deterioration in fundamentals and could exert near-term pressure on the stock.

Analysis

ARS Pharmaceuticals reported a quarterly EPS loss of $0.42, in line with the Zacks consensus, versus EPS of $0.52 a year ago — a year-over-year swing of $0.94 to the downside. The print meets expectations but the move from profit to loss signals a meaningful deterioration in fundamentals and could exert near-term pressure on the stock.